Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lifitegrast
Drug ID BADD_D01290
Description Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805].
Indications and Usage For the treatment of signs and symptoms of keratoconjunctivitis sicca (dry eye syndrome).
Marketing Status approved
ATC Code S01XA25
DrugBank ID DB11611
KEGG ID D10374
MeSH ID C575157
PubChem ID 11965427
TTD Drug ID D0Q9EV
NDC Product Code 65392-2803; 17337-0431; 59116-5170; 63592-3385; 66005-0049; 59651-445; 64552-4088; 64552-4089; 71796-011; 58159-054; 65129-1428; 69766-074; 66039-948; 0078-0911
UNII 038E5L962W
Synonyms lifitegrast | L-phenylalanine, n-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)- | (2S)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid | Xiidra | SHP-606 | SHP606 | lifitegrast ophthalmic solution | SAR 1118 | SAR-1118
Chemical Information
Molecular Formula C29H24Cl2N2O7S
CAS Registry Number 1025967-78-5
SMILES CS(=O)(=O)C1=CC=CC(=C1)CC(C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4) C=CO5)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eyelid rash23.03.13.020; 06.04.04.0170.003406%Not Available
Pharyngeal paraesthesia22.04.05.018; 17.02.06.0350.001362%Not Available
Allergic reaction to excipient10.01.01.0350.001362%Not Available
Eyelash changes06.06.04.0250.002043%Not Available
Floppy eyelid syndrome06.06.04.026; 23.07.04.0400.001362%Not Available
Illness08.01.03.0910.003806%Not Available
Instillation site burn12.07.01.057; 08.02.01.057; 23.03.11.0370.008173%Not Available
Instillation site coldness12.07.01.058; 08.02.01.0580.001362%Not Available
Instillation site discharge23.03.03.089; 12.07.01.059; 08.02.01.0590.019953%Not Available
Instillation site dryness12.07.01.060; 08.02.01.0600.008854%Not Available
Instillation site erythema23.03.06.025; 12.07.01.061; 08.02.01.0610.050803%Not Available
Instillation site foreign body sensation12.07.01.062; 08.02.01.0620.009055%Not Available
Instillation site hypersensitivity08.02.01.063; 12.07.01.063; 10.01.03.0600.005449%Not Available
Instillation site inflammation12.07.01.064; 08.02.01.0640.010898%Not Available
Instillation site lacrimation12.07.01.065; 08.02.01.0650.037661%Not Available
Instillation site odour12.07.01.066; 08.02.01.0660.001362%Not Available
Instillation site paraesthesia17.02.06.052; 12.07.01.067; 08.02.01.0670.002925%Not Available
Instillation site pruritus23.03.12.014; 12.07.01.068; 08.02.01.0680.044192%Not Available
Instillation site rash23.03.13.027; 12.07.01.069; 08.02.01.0690.001362%Not Available
Instillation site swelling12.07.01.070; 08.02.01.0700.019953%Not Available
Instillation site vesicles08.02.01.071; 23.03.01.037; 12.07.01.0710.001362%Not Available
Periorbital swelling23.04.01.025; 10.01.05.025; 06.08.03.0320.005168%Not Available
Pharyngeal swelling22.04.05.0280.002444%Not Available
Sinus pain22.12.03.0230.004087%
Swelling of eyelid23.04.01.026; 10.01.05.026; 06.04.04.0180.011298%Not Available
Taste disorder17.02.07.029; 07.14.03.0040.022877%Not Available
Therapeutic response shortened08.06.01.0620.001362%Not Available
The 6th Page    First    Pre   6    Total 6 Pages